[1]	GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019[J]. Lancet Public Health, 2022, 7(2):e105-e125. Cited in this article [1]

[2]	Otto E, Knapstein PR, Jahn D, et al. Crosstalk of brain and bone-clinical observations and their molecular bases[J]. Int J Mol Sci, 2020, 21(14):4946. Cited in this article [1]

[3]	Rajamaki B, Hartikainen S, Tolppanen AM, et al. The effect of comorbidities on survival in persons with Alzheimer's disease: a matched cohort study[J]. BMC Geriatr, 2021, 21(1):173. Cited in this article [1]

[4]	Zhou R, Zhou H, Rui L, et al. Bone loss and osteoporosis are associated with conversion from mild cognitive impairment to Alzheimer's disease[J]. Curr Alzheimer Res, 2014, 11(7):706-713. Cited in this article [1]

[5]	Pu Z, Tang X, Fei Y, et al. Bone metabolic biomarkers and bone mineral density in male patients with early-stage Alzheimer's disease[J]. Eur Geriatr Med, 2020, 11(3):403-408. Cited in this article [2]

[6]	Boo YY, Jutila OE, Cupp MA, et al. The identification of established modifiable mid-life risk factors for cardiovascular disease which contribute to cognitive decline: Korean Longitudinal Study of Aging (KLoSA)[J]. Aging Clin Exp Res, 2021, 33(9):2573-2586. Cited in this article [1]

[7]	Devkota S, Williams TD, Wolfe MS, et al. Familial Alzheimer's disease mutations in amyloid protein precursor alter proteolysis by γ-secretase to increase amyloid β-peptides of ≥45 residues[J]. J Biol Chem, 2021,296:100281. Cited in this article [1]

[8]	Shi T, Shen S, Shi Y, et al. Osteocyte-derived sclerostin impairs cognitive function during ageing and Alzheimer's disease progression[J]. Nat Metab, 2024, 6(3):531-549. Cited in this article [2]

[9]	LLabre JE, Gil C, Amatya N, et al. Degradation of bone quality in a transgenic mouse model of Alzheimer's disease[J]. J Bone Miner Res, 2022, 37(12):2548-2565. Cited in this article [1]

[10]	Rinotas V, Liepouri F, Ouzouni MD, et al. Structure-based discovery of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis inhibitors[J]. Int J Mol Sci, 2023, 24(14):11290. Cited in this article [1]

[11]	Pan JX, Tang F, Xiong F, et al. APP promotes osteoblast survival and bone formation by regulating mitochondrial function and preventing oxidative stress[J]. Cell Death Dis, 2018, 9(11):1077. Cited in this article [1]

[12]	Sun J, Li Q, Wang S, et al. Establishment and evaluation of a rat model of medial malleolar fracture with vascular injury[J]. Orthop Surg, 2022, 14(10):2701-2710. Cited in this article [1]

[13]	Zou B, Xiong Z, Yu Y, et al. Rapid selenoprotein activation by selenium nanoparticles to suppresses osteoclastogenesis and pathological bone loss[J]. Adv Mater, 2024, 36(27):e2401620. Cited in this article [1]

[14]	Wong SK. Glycogen synthase kinase-3 beta (GSK3β) as a potential drug target in regulating osteoclastogenesis: an updated review on current evidence[J]. Biomolecules, 2024, 14(4):502. Cited in this article [1]

[15]	Yang H, Li J, Li X, et al. Based on molecular structures: amyloid-β generation, clearance, toxicity and therapeutic strategies[J]. Front Mol Neurosci, 2022,31,15:927530. Cited in this article [1]

[16]	Lin Y, Chen T, Chen J, et al. Endogenous Aβ induces osteoporosis through an mTOR-dependent inhibition of autophagy in bone marrow mesenchymal stem cells (BMSCs)[J]. Ann Transl Med, 2021, 9(24):1794. Cited in this article [1]

[17]	Guo HH, Xiong L, Pan JX, et al. Hepcidin contributes to swedish mutant APP-induced osteoclastogenesis and trabecular bone loss[J]. Bone Res, 2021, 9(1):31. Cited in this article [1]

[18]	Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities[J]. Cell, 2017, 169(6):985-999. Cited in this article [2]

[19]	Wang Q, Huang X, Su Y, et al. Activation of Wnt/β-catenin pathway mitigates blood-brain barrier dysfunction in Alzheimer's disease[J]. Brain, 2022, 145(12):4474-4488. Cited in this article [1]

[20]	Dengler-Crish CM, Ball HC, Lin L, et al. Evidence of Wnt/β-catenin alterations in brain and bone of a tauopathy mouse model of Alzheimer's disease[J]. Neurobiol Aging, 2018,67:148-158. Cited in this article [1]

[21]	Marini F, Giusti F, Palmini G, et al. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders[J]. Osteoporos Int, 2023, 34(2):213-238. Cited in this article [2]

[22]	Jiang H, Zhang Z, Yu Y, et al. Drug discovery of DKK1 inhibitors[J]. Front Pharmacol, 2022,13:847387. Cited in this article [1]

[23]	Dengler-Crish CM, Ball HC, Lin L, et al. Evidence of Wnt/β-catenin alterations in brain and bone of a tauopathy mouse model of Alzheimer's disease[J]. Neurobiol Aging, 2018,67:148-158. Cited in this article [1]

[24]	Yan Y, Wang L, Ge L, et al. Osteocyte-mediated translation of mechanical stimuli to cellular signaling and its role in bone and non-bone-related clinical complications[J]. Curr Osteoporos Rep, 2020, 18(1):67-80. Cited in this article [1]

[25]	Marini F, Giusti F, Palmini G, et al. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders[J]. Osteoporos Int, 2023, 34(2):213-238. Cited in this article [1]

[26]	Kim J, Han W, Park T, et al. Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains[J], Nat Commun, 2022, 13(1):738. Cited in this article [1]

[27]	Jia L, Xu H, Chen S, et al. The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease[J]. Alzheimers Dement, 2020, 16(12):1613-1623. Cited in this article [1]

[28]	Malm TM, Koistinaho M, Pärepalo M, et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice[J]. Neurobiol Dis, 2005, 18(1):134-142. Cited in this article [1]

[29]	Souza LS, Rochette NF, Pedrosa DF, et al. Role of APOE gene in bone mineral density and incidence of bone fractures in brazilian postmenopausal women[J]. J Clin Densitom. 2018, 21(2):227-235. Cited in this article [1]

[30]	Kim WS, Kim HJ, Lee ZH, et al. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB[J]. Exp Cell Res, 2013, 319(4):436-446. Cited in this article [1]

[31]	Wang YN, Yu L, Wang T, et al. Apolipoprotein E facilitates titanium implant osseointegration by regulating osteogenesis-lipogenesis balance[J]. Int J Biol Macromol, 2023,236:123998. Cited in this article [1]

[32]	Thakur S, Dhapola R, Sarma P, et al. Neuroinflammation in Alzheimer's disease: current progress in molecular signaling and therapeutics[J]. Inflammation, 2023, 46(1):1-17. Cited in this article [1]

[33]	Matsumoto Y, Rottapel R. Bone dynamics and inflammation: lessons from rare diseases[J]. Immunol Med, 2020, 43(2):61-64. Cited in this article [1]

[34]	Khan KM, Balasubramanian N, Gaudencio G, et al. Human tau-overexpressing mice recapitulate brainstem involvement and neuropsychiatric features of early Alzheimer's disease[J]. Acta Neuropathol Commun, 2023, 11(1):57. Cited in this article [1]

[35]	Rani V, Verma R, Kumar K, et al. Role of pro-inflammatory cytokines in Alzheimer's disease and neuroprotective effects of pegylated self-assembled nanoscaffolds[J]. Curr Res Pharmacol Drug Discov, 2022,4:100149. Cited in this article [1]

[36]	Gilbert LC, Chen H, Lu X, et al. Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts[J]. Bone, 2013, 56(1):174-183. Cited in this article [1]

[37]	Kushioka J, Chow SK, Toya M, et al. Bone regeneration in inflammation with aging and cell-based immunomodulatory therapy[J]. Inflamm Regen, 2023, 43(1):29. Cited in this article [1]

[38]	Kalra A, Teixeira AL, Diniz BS, et al. Association of vitamin D levels with incident all-cause dementia in longitudinal observational studies: a systematic review and meta-analysis[J]. J Prev Alzheimers Dis, 2020, 7(1):14-20. Cited in this article [1]

[39]	Soares JZ, Valeur J, Šaltytė Benth J, et al. Vitamin D in Alzheimer's disease: low levels in cerebrospinal fluid despite normal amounts in serum[J]. J Alzheimers Dis, 2022, 86(3):1301-1314. Cited in this article [1]

[40]	Mokry LE, Ross S, Morris JA, et al. Genetically decreased vitamin D and risk of Alzheimer disease[J]. Neurology, 2016, 87(24):2567-2574. Cited in this article [1]

[41]	Zhang H, Wang T, Han Z, et al. Impact of vitamin D binding protein levels on Alzheimer's disease: a mendelian randomization study[J]. J Alzheimers Dis, 2020, 74(3):991-998. Cited in this article [1]

[42]	Zhang H, Wang T, Han Z, et al. Impact of vitamin D binding protein levels on Alzheimer's disease: a mendelian randomization study[J]. J Alzheimers Dis, 2020, 74(3):991-998. Cited in this article [1]

[43]	Li Y, Zhao P, Jiang B, et al. Modulation of the vitamin D/vitamin D receptor system in osteoporosis pathogenesis: insights and therapeutic approaches[J]. J Orthop Surg Res, 2023, 18(1):860. Cited in this article [2]

[44]	De Martinis M, Ginaldi L, Sirufo MM, et al. IL-33/Vitamin D crosstalk in psoriasis-associated osteoporosis[J]. Front Immunol, 2021,11:604055. Cited in this article [1]

[45]	Diachenko AI, Rodin IA, Krasnova TN, et al. The role of vitamin K in the development of neurodegenerative diseases[J]. Biochemistry (Mosc), 2024, 89(Suppl 1):S57-S70. Cited in this article [1]

[46]	Ding H, Reiss AB, Pinkhasov A, et al. Plants, plants, and more plants: plant-derived nutrients and their protective roles in cognitive function, Alzheimer's disease, and other dementias[J]. Medicina (Kaunas), 2022, 58(8):1025. Cited in this article [1]

[47]	Sharlow ER, Llaneza DC, Tewari BP, et al. Pharmacological profiling identifies divergent chemosensitivities of differentiating and maturing iPSC-derived human cortical neuron populations[J]. FEBS J, 2023, 290(20):4950-4965. Cited in this article [1]

[48]	Fu X, Shea MK, Dolnikowski GG, et al. Vitamin D and vitamin K concentrations in human brain tissue are influenced by freezer storage time: the memory and aging project[J]. J Nutr, 2021, 151(1):104-108. Cited in this article [1]

[49]	Pomara N, Imbimbo BP. Do anti-Aβ monoclonal antibodies lower brain plaques in Alzheimer patients through microglia activation?[J]. Alzheimers Dement, 2024, 20(3):2289-2290. Cited in this article [1]

[50]	Rahman A, Hossen MA, Chowdhury MFI, et al. Aducanumab for the treatment of Alzheimer's disease: a systematic review[J]. Psychogeriatrics, 2023, 23(3):512-522. Cited in this article [1]

[51]	Filippi M, Cecchetti G, Spinelli EG, et al. Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review[J]. JAMA Neurol, 2022, 79(3):291-304. Cited in this article [1]

[52]	Choi Y, Joh Y, Ryu JS, et al. Endogenous Aβ peptide promote Aβ oligomerization tendency of spiked synthetic Aβ in Alzheimer's disease plasma[J]. Mol Cell Neurosci, 2021,111:103588. Cited in this article [1]

[53]	Tingen HSA, Tubben A, van 't Oever JH, et al. Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review[J]. Eur J Nucl Med Mol Imaging, 2023, 51(1):93-109. Cited in this article [1]

[54]	Chen C, Yang C, Wang J, et al. Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer's disease[J]. J Pineal Res, 2021, 71(4):e12774. Cited in this article [1]

[55]	Chen D, Mei Y, Kim N, et al. Melatonin directly binds and inhibits death-associated protein kinase 1 function in Alzheimer's disease[J]. J Pineal Res, 2020, 69(2):e12665. Cited in this article [1]

[56]	Yodthong T, Kedjarune-Leggat U, Smythe C, et al. l-Quebrachitol promotes the proliferation, differentiation, and mineralization of MC3T3-E1 cells: involvement of the BMP-2/Runx2/MAPK/Wnt/β-catenin signaling pathway[J]. Molecules, 2018, 23(12):3086. Cited in this article [1]

[57]	Chen W, Huang Y, Han J, et al. Immunomodulatory effects of mesenchymal stromal cells-derived exosome[J]. Immunol Res, 2016, 64(4):831-840. Cited in this article [1]

[58]	Yuyama K, Sun H, Sakai S, et al. Decreased amyloid-β pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in Alzheimer model mice[J]. J Biol Chem, 2014, 289(35):24488-24498. Cited in this article [1]

[59]	Ren L, Song ZJ, Cai QW, et al. Adipose mesenchymal stem cell-derived exosomes ameliorate hypoxia/serum deprivation-induced osteocyte apoptosis and osteocyte-mediated osteoclastogenesis in vitro[J]. Biochem Biophys Res Commun, 2019, 508(1):138-144. Cited in this article [1]

[60]

Shin JW, Lee JK, Lee JE, et al. Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell-derived factor-1α in an Alzheimer's disease mouse model[J]. Stem Cells, 2011, 29(7):1075-1089. Cited in this article [1]

[61]	Han J, Chitu V, Stanley ER, et al. Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges[J]. Cell Mol Life Sci, 2022, 79(4):219. Cited in this article [1]

[62]	Ebetino FH, Sun S, Cherian P, et al. Bisphosphonates: the role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use[J]. Bone, 2022,156:116289. Cited in this article [1]

[63]	Zullo AR, Zhang T, Lee Y, et al. Effect of bisphosphonates on fracture outcomes among frail older adults[J]. J Am Geriatr Soc, 2019, 67(4):768-776. Cited in this article [1]

[64]	Driscoll I, Resnick SM. Testosterone and cognition in normal aging and Alzheimer's disease: an update[J]. Curr Alzheimer Res, 2007, 4(1):33-45. Cited in this article [1]